Results from COSMOS study of Olysio + Sovaldi for HCV published in The Lancet-Medivir
Medivir has announced that results from the Phase II COSMOS clinical study were published in The Lancet, demonstrating that 92 percent of genotype 1 chronic Hepatitis C virus adult patients treated with Olysio + Sovaldi (simeprevir + sofosbuvir) achieved sustained virologic response 12 weeks after the end of treatment (SVR12). The study included patients with compensated cirrhosis and prior null response to treatment with pegylated interferon and ribavirin.
The treatment regimen with simeprevir and sofosbuvir resulted in consistent SVR12 rates regardless of degree of fibrosis, and was an effective and well-tolerated therapeutic regimen in both treatment-na�ve and prior null-responder patients. See: "Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study." Eric Lawitz et al. The Lancet, Early Online Publication, 28 July 2014 doi:10.1016/S0140-6736(14)61036-9
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins